Last reviewed · How we verify
AZD5718 tablet, Formulation A — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AZD5718 tablet, Formulation A (AZD5718 tablet, Formulation A) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AZD5718 tablet, Formulation A TARGET | AZD5718 tablet, Formulation A | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AZD5718 tablet, Formulation A CI watch — RSS
- AZD5718 tablet, Formulation A CI watch — Atom
- AZD5718 tablet, Formulation A CI watch — JSON
- AZD5718 tablet, Formulation A alone — RSS
Cite this brief
Drug Landscape (2026). AZD5718 tablet, Formulation A — Competitive Intelligence Brief. https://druglandscape.com/ci/azd5718-tablet-formulation-a. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab